Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies
Authors:
- Ivana LagrecaILIvana Lagreca
- Vincenzo NasilloVNVincenzo Nasillo
- Patrizia BarozziPBPatrizia Barozzi
- Ilaria CastelliICIlaria Castelli
- Sabrina BassoSBSabrina Basso
- Sara CastellanoSCSara Castellano
- Ambra PaoliniAPAmbra Paolini
- Monica MaccaferriMMMonica Maccaferri
- Elisabetta ColaciECElisabetta Colaci
- Daniela ValleriniDVDaniela Vallerini
- Patrizia NataliPNPatrizia Natali
- Daria DebbiaDDDaria Debbia
Open Access
Abstract
Multiple Myeloma (MM) typically originates from underlying precursor conditions, known as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM). Validated risk factors, related to the main features of the clonal plasma cells, are employed in the current prognostic models to assess long-term probabilities of progression to MM. In addition, new prognostic immunologic parameters, measuring protective MM-specific T-cell responses, could help to identify patients with shorter time-to-progression. In this report, we described a novel Multi-antigenic Myeloma-specific (MaMs) T-cell assay, based on ELISpot technology, providing simultaneous evaluation of T-cell responses towards ten different MM-associated antigens. When performed during long-term follow-up (mean 28 months) of 33 patients with either MGUS or SMM, such deca-antigenic myeloma-specific immunoassay allowed to significantly distinguish between stable vs. progressive disease (p < 0.001), independently from the Mayo Clinic risk category. Here, we report the first clinical experience showing that a wide (multi-antigen), standardized (irrespective to patients’ HLA), MM-specific T-cell assay may routinely be applied, as a promising prognostic tool, during the follow-up of MGUS/SMM patients. Larger studies are needed to improve the antigenic panel and further explore the prognostic value of MaMs test in the risk assessment of patients with monoclonal gammopathies.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (AIRC) (#20624, #CN00000041, CP2_10/2018, 2526393, 08069119, 08045818, SIES Fellowship 2018–2019)
- PNRR CN3 Terapia Genica-Spoke 2 (#20624, #CN00000041, CP2_10/2018, 2526393, 08069119, 08045818, SIES Fellowship 2018–2019)
- Progetto Dipartimenti di Eccellenza MIUR 2017 (#20624, #CN00000041, CP2_10/2018, 2526393, 08069119, 08045818, SIES Fellowship 2018–2019)
- “Charity Dinner Initiative” (#20624, #CN00000041, CP2_10/2018, 2526393, 08069119, 08045818, SIES Fellowship 2018–2019)
- Associazione Italiana Lotta alle Leucemie, Linfoma e Mieloma (AIL)—Sezione “Luciano Pavarotti”—Modena-ONLUS (#20624, #CN00000041, CP2_10/2018, 2526393, 08069119, 08045818, SIES Fellowship 2018–2019)
- Fondazione IRIS ceramica group (#20624, #CN00000041, CP2_10/2018, 2526393, 08069119, 08045818, SIES Fellowship 2018–2019)
- Fondazione Regionale per la Ricerca Biomedica (#20624, #CN00000041, CP2_10/2018, 2526393, 08069119, 08045818, SIES Fellowship 2018–2019)
- Regione Lombardia, Progetto POR-FESR (#20624, #CN00000041, CP2_10/2018, 2526393, 08069119, 08045818, SIES Fellowship 2018–2019)
- Fondazione IRCCS Policlinico San Matteo di Pavia (#20624, #CN00000041, CP2_10/2018, 2526393, 08069119, 08045818, SIES Fellowship 2018–2019)
- Fondazione Just Italia (#20624, #CN00000041, CP2_10/2018, 2526393, 08069119, 08045818, SIES Fellowship 2018–2019)
- Italian Society of Experimental Hematology (#20624, #CN00000041, CP2_10/2018, 2526393, 08069119, 08045818, SIES Fellowship 2018–2019)
This publication has 52 references indexed in Scilit:
- WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and donor lymphocyte infusionsBlood, 2013
- Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myelomaBlood, 2010
- Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodiesNeoplasma, 2010
- Melan-A/MART1 Analog Peptide Triggers Anti-myeloma T-cells Through Crossreactivity With HM1.24Journal of Immunotherapy, 2009
- Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myelomaBlood, 2008
- Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myelomaBlood, 2007
- Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathyJournal of Experimental Medicine, 2007
- NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responsesBlood, 2005
- Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptorBlood, 2005
- Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal GammopathyJournal of Experimental Medicine, 2003